EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?

Piotr Eder, Adam Fabisiak, Hubert Zatorski, Liliana Łykowska-Szuber, Kamila Stawczyk-Eder, Katarzyna Waszak, Magdalena Gawron-Kiszka, Patrycja Dudek, Katarzyna Bzdęga, Renata Talar-Wojnarowska

BioDrugs · 2026-05 · 40 (3) · 361-380

DOI: 10.1007/s40259-026-00770-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioDrugs, online erschienen am 07.03.2026. Verfasst von Piotr Eder und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Dietetics and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland. piotreder@ump.edu.pl. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Medical Research Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, substantial progress has been achieved in the development of novel therapeutic options for inflammatory bowel disease (IBD). Despite these advances, a significant proportion of patients continue to experience either primary nonresponse or secondary loss of response to biologic agents or small-molecule therapies. In addition, many patients present with heterogeneous and often difficult-to-manage extraintestinal manifestations, highlighting the persistent unmet needs in IBD management. Consequently, multiple therapeutic strategies have been explored to overcome these challenges and to improve long-term disease control. Among emerging approaches, advanced combination therapy (ACT)-defined as the concomitant use of monoclonal antibodies and/or oral small-molecule agents with distinct mechanisms of action-has attracted increasing interest in recent years. ACT aims to enhance therapeutic efficacy, address complex disease phenotypes, and potentially prevent or delay treatment failure. In this review, we summarize the currently available evidence on how to optimally apply combination therapeutic strategies in IBD. Key aspects discussed include the rationale for selecting agents with complementary mechanisms of action, the hypothetical timing and duration of combination treatment, and the clinical criteria that may guide the selection of specific ACT algorithms. Evidence derived from real-world studies and completed randomized clinical trials, including the landmark VEGA trial, is critically reviewed. Furthermore, we present data from ongoing clinical trials-both industry- and investigator-initiated-as well as emerging research on bispecific therapeutic molecules in IBD, which combine two molecular targets within a single compound. Together, these data provide a comprehensive overview of the current and future role of ACT in IBD management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesAntibodies, MonoclonalHumansDrug Therapy, Combination

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Gastroenterology, Dietetics and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland. piotreder@ump.edu.pl.
  • Department of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland.
  • Department of Gastroenterology, Dietetics and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland.
  • Department of Gastroenterology and Hepatology, Medical University of Silesia, Katowice, Poland.
  • Chair and Department of Genetics and Pharmaceutical Microbiology, Poznan University of Medical Sciences, Poznan, Poland.

Förderung

  • Medical Research Agency

Zitieren

APA

Eder, P., Fabisiak, A., Zatorski, H., Łykowska-Szuber, L., Stawczyk-Eder, K., Waszak, K., Gawron-Kiszka, M., Dudek, P., Bzdęga, K., & Talar-Wojnarowska, R. (2026). Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?. BioDrugs, 40(3), 361-380. https://doi.org/10.1007/s40259-026-00770-4

Vancouver

Eder P, Fabisiak A, Zatorski H, Łykowska-Szuber L, Stawczyk-Eder K, Waszak K, et al. Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?. BioDrugs. 2026;40(3):361-380. doi:10.1007/s40259-026-00770-4

BibTeX
@article{Eder2026,
  author = {Eder, Piotr and Fabisiak, Adam and Zatorski, Hubert and Łykowska-Szuber, Liliana and Stawczyk-Eder, Kamila and Waszak, Katarzyna and Gawron-Kiszka, Magdalena and Dudek, Patrycja and Bzdęga, Katarzyna and Talar-Wojnarowska, Renata},
  title = {Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?},
  journal = {BioDrugs},
  year = {2026},
  volume = {40},
  number = {3},
  pages = {361--380},
  doi = {10.1007/s40259-026-00770-4}
}
Kostenlos starten →